Picture of Prothena logo

PRTA — Prothena News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapHigh Flyer

Prothena Corporation PLC expected to post a loss of 47 cents a share - Earnings Preview

* Prothena Corporation PLC  PRTA.OQ   PRTA.O  is expected
to show
a rise in quarterly revenue when it reports  results on February
13 (estimated). 
    * The Dublin Ireland; Republic of-based   company is
expected to
report  a 2,386.7% increase in revenue to $29.144 million from
$1.17 million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Prothena
Corporation PLC
is for a loss of 47 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Prothena
Corporation PLC is $81​, above​ its last closing price
of $53.38. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.53       -0.53      -0.97     Missed  -83.5
 Jun. 30 2022  -0.58       -0.52      -0.88     Missed  -68.1
 Mar. 31 2022  -0.75       -0.68      -0.78     Missed  -15.3​
 Dec. 31 2021  -0.59       -0.58      -0.71     Missed  -21.6
 ​​Sep.        2.28        2.28       2.13      Missed  -6.5
 30 2021                                                
 Jun. 30 2021  1.69        1.00       0.58      Missed  -41.9​
 Mar. 31 2021  -0.69       -0.54      -0.91     Missed  -67.9
 Dec. 31 2020  -0.81       -0.77      -0.77     Met     -0.1
 This summary was machine generated February 11 at 01:27 GMT. 
All figures in US dollars  unless otherwise stated

Recent news on Prothena

See all news